Sreekanth K. Chaguturu - May 11, 2022 Form 3/A - restatement Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Sreekanth K. Chaguturu
Stock symbol
CVS
Transactions as of
May 11, 2022
Transactions value $
$0
Form type
3/A - RESTATEMENT
Date filed
6/6/2022, 05:03 PM
Date Of Original Report
May 19, 2022
Next filing
Jun 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding CVS Common Stock (RSU) 996 May 11, 2022 Direct F1
holding CVS Common Stock (RSU) 354 May 11, 2022 Direct F2
holding CVS Common Stock (RSU) 2.15K May 11, 2022 Direct F3
holding CVS Common Stock (RSU) 1.26K May 11, 2022 Direct F4
holding CVS Common Stock (RSU) 2.09K May 11, 2022 Direct F5
holding CVS Common Stock (RSU) 2.78K May 11, 2022 Direct F6
holding CVS Common Stock (RSU) 6.18K May 11, 2022 Direct F7
holding CVS Common Stock 2.34K May 11, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option May 11, 2022 Common Stock 5.95K $75.27 Direct F8
holding CVS Stock Option May 11, 2022 Common Stock 9.58K $58.34 Direct F9
holding CVS Stock Option May 11, 2022 Common Stock 9.5K $74.30 Direct F10
holding CVS Stock Option May 11, 2022 Common Stock 13K $101.09 Direct F11

Explanation of Responses:

Id Content
F1 Consists of Restricted Stock Units (RSUs) awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse on the third anniversary of the grant date.
F2 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
F3 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F4 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F5 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
F6 Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
F7 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
F8 Option becomes exercisable in four equal annual installments, commencing 11/29/2020.
F9 Option becomes exercisable in four equal annual installments, commencing 4/1/2021.
F10 Option becomes exercisable in four equal annual installments, commencing 4/1/2022.
F11 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.